Introduction
Endometrial cancer is the third most common gynecologic malignancy in Japan, where incidence has dramatically increased over the last decade. Although premalignant lesions of endometrial cancer are well characterized, the molecular pathways of endometrial carcinogenesis remain unclear. Previous genetic analyses have identified several genetic abnormalities involved in endometrial carcinogenesis. The mutations most frequently observed in endometrial cancers are in the genes PTEN and K-ras, whereas only a small percentage of endometrial cancers have p53 mutations (Enomoto et al., 1991; Tashiro et al., 1997; Inoue, 2001) . As PTEN and K-ras mutations have also been detected in precursor lesions, they are thought to be early events in endometrial carcinogenesis (Levine et al., 1998; Maxwell et al., 1998; Mutter et al., 1999; Inoue, 2001; Kanaya et al., 2005) . However, the specific combinations of mutations required to form endometrial cancer cells are unknown. Currently available in vitro models, in which specific genetic factors are introduced or knocked out in human primary endometrial cells, have been a great help in characterizing molecular pathways of endometrial carcinogenesis. However, in classical tissue culture using plastic or glass dishes, endometrial epithelial cells lose their proliferative capacity during ongoing cultivation over several days, whereas stromal cells are relatively easily cultured long-term. Most investigators in this field have tried to develop endometrial cell cultures with a mixture of stromal and epithelial cells and/or organotipic cultures, but only short-term cultures have been obtained using such methods (Akoum et al., 1996; Classen-Linke et al., 1997; Arnold et al., 2001) .
We previously extended the life span of cultured endometrial epithelial cells by introducing the human papillomavirus (HPV) E6/E7 gene and human telomerase reverse transcriptase (hTERT) gene (Kyo et al., 2003) . Introduction of HPV E6/E7 prevented premature senescence caused by activation of the Rb/p16 pathway, which is commonly observed in in vitro culture of most types of epithelial cells at early population doublings (PD) (Kiyono et al., 1998) . Introduction of hTERTactivated telomerase, stabilized telomeres and prevented telomere-based replicative senescence at later PDs.
These cells, which we designated EM-E6/E7/TERT cells, continued to grow for >250 PDs, and they appear to be immortal. However, they did not form colonies in soft agar or form tumors in nude mice, and they never exhibited a transformed phenotype. Additional genetic factors are therefore required for transformation of endometrial epithelial cells, and the most promising candidates are specific mutations of key oncogenes and tumor suppressor genes, including K-ras and PTEN.
In addition to gene mutation, widespread chromosome alterations induced by chromosomal instability may also play roles in carcinogenesis. In particular, chromosomal instability caused by critical shortening of telomeres has been proposed as a trigger of cancer initiation in most epithelial cells (Chin et al., 1999; Artandi and DePinho, 2000) . We have therefore conducted studies aimed at determining whether chromosomal instability owing to telomere loss in immortalized cells affects their predisposition to carcinogenesis.
In the present study, to examine genetic requirements for endometrial carcinogenesis, we genetically manipulated endometrial epithelial cells and successfully created tumorigenic cells with intact chromosomes. These cells provide an attractive in vitro model not only for dissection of the molecular mechanisms of endometrial carcinogenesis, but also for testing and development of specific inhibitors of oncogenic pathways.
Results

Establishment of immortalized endometrial epithelial cells with or without chromosome abnormality
Previously established immortalized endometrial epithelial cells (EM-E6/E7/TERT cells) were generated by introducing HPV16 E6 and E7 genes together with the hTERT gene into normal endometrial epithelial cells. EM-E6/E7/TERT cells have stabilized telomeres and basically normal karyotypes, and they lack transformed phenotypes (Kyo et al., 2003) (Figure 1 ). We first examined whether the chromosome abnormality induced by critical telomere shortening affects predisposi- (Kyo et al., 2003) ( Figure 1 ), at which time they had severe chromosomal abnormalities with varying numbers of chromosomes, which were apparently caused by chromosome fusion or loss via critical shortening of telomeres. We thus attempted to immortalize these EM-E6/E7 cells, and we evaluated their potential for transformation. We introduced the hTERT gene immediately before the majority of the EM-E6/E7 cells entered crisis (Figure 1 ). When hTERT was introduced later than PD 35, the cells failed to survive the crisis. We do not know whether this was due to poor transduction efficiency of hTERT, due to decreased growth rates of cells, or due to the inability of the introduced hTERT to sufficiently protect the telomere ends in such a short period. In contrast, when hTERT was introduced into EM-E6/E7 cells at PD35, the resulting cells survived crisis, were still growing at PD 250 (last cell counting), and appeared to be immortal with recovered telomere length; these cells were designated as EM-E6/E7(TERT) (Figure 1 Mutations of PTEN and K-ras genes are frequent in endometrial cancer, but are not likely to naturally coexist Previous studies using clinical samples revealed that PTEN and K-ras mutations are the most common of the genetic abnormalities that have been detected in endometrial cancer with endometrioid subtype (Enomoto et al., 1991; Tashiro et al., 1997; Inoue, 2001; Kanaya et al., 2005) . We examined the frequencies of PTEN and K-ras mutations in samples of 56 Japanese endometrial cancers obtained from patients surgically treated in our hospital. DNA sequencing analysis revealed that 22 of the 56 endometrial cancers we examined (39.3%) had a PTEN mutation; 10 had a point mutation, and 12 had a frameshift mutation (Table 1 ) (Kanaya et al., 2005) . K-ras mutations were detected in 10 of the tumors (17.9%). A total of 29 of the tumors (51.8%) had a PTEN mutation and/or a K-ras mutation; two of those 29 tumors had both mutations. In the remaining 27 tumors, these two mutations did not coexist. We next examined correlation of PTEN and K-ras mutations with microsattelite instability (MSI). All 10 tumors with a PTEN frameshift mutation exhibited high-frequency MSI (Kanaya et al., 2005) , whereas only three of the nine tumors with a K-ras mutation exhibited high-frequency MSI (status of MSI was unknown in one tumor with a K-ras mutation), indicating that PTEN frameshift mutation may be caused by mismatch-repair (MMR) deficiency, which is distinct from the mechanisms responsible for K-ras mutations. These findings suggest that PTEN and K-ras mutations act independently of each other as genetic factors in endometrial carcinogenesis. 
Abbreviations: Pt, patient; MSI, microsattelite instability; H, high frequency; L, low frequency; S, stable; ND, not done; FS, frameshift mutation; PM, point mutation.
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Creation of tumorigenic endometrial epithelial cells with intact chromosomes by introducing mutant K-ras allele The above results of genetic analysis suggest that introduction of mutant PTEN and K-ras alleles is a promising approach to create endometrial cancer cells. We therefore specifically inhibited the PTEN gene with short hairpin RNA (shRNA) or introduced an oncogenic K-ras (K-rasV12G) allele in EM-E6/E7/TERT cells. The major downstream effect of PTEN mutation is activation of Akt, which mediates cell survival signals that lead to antiapoptotic pathways (Stambolic et al., 1998) . To intensify the effect of PTEN mutation, we introduced a constitutively active form of Akt into EM-E6/E7/TERT cells. The effects of these genetic manipulations were examined by Western blot analysis. Figure 2 shows that the shRNA inhibited PTEN protein expression by approximately 50%, compared to cells with control shRNA. As expected, introduction of the constitutively active form of Akt resulted in increased levels of phosphorylated Akt, and introduction of mutant K-ras resulted in increased levels of phosphorylated Erk. We examined in vitro growth of the EM-E6/E7/TERT cells with the above genetic manipulations. Under normal culture conditions, there were no significant differences in exponential growth rate between cells transfected with vector alone and cells transfected with mutant K-ras, Akt or shRNA-PTEN. However, saturation density of cells with mutant K-ras or Akt was significantly greater than that of vector-only controls (Figure 3a) . When cells were cultured under low-serum conditions with 0.5% fetal calf serum (FCS), the cells with mutant K-ras or Akt had a higher growth rate than the vector-only controls on day 5 (Figure 3b ), but only the cells with mutant K-ras had a significantly higher growth rate (Po0.05). The morphology of the cells transfected with mutant K-ras changed to small and round shapes, whereas other cells retained the morphology of the parental cells (Figure 3c ). Anchorageindependent growth was then examined using a soft agar colony formation assay. Whereas the vector control or cells transfected with shRNA-control or shRNA-PTEN exhibited a modest ability to form colonies, cells with Akt or mutant K-ras formed significantly greater numbers of colonies than their controls (Po0.01) (Figure 4 ). When tumorigenicity was examined, only cells with mutant K-ras consistently formed tumors in mice (Figure 5a ). The tumors that formed in the mice were then histologically examined, and were found to be undifferentiated adenocarcinoma with severe nuclear atypia (Figure 5b ). The invasive ability of cells was examined by Matrigel invasion assay. Cells with mutant K-ras exhibited significant invasive ability, compared to vector controls, but cells with mutant Akt or sh-RNA PTEN did not (Figure 5c ). Thus, it appears that introduction of mutant K-ras is sufficient to transform EM-E6/E7/TERT cells. Overexpression of Akt was insufficient for complete transformation of EM-E6/E7/TERT cells, but it conferred anchorage-independent growth capacity.
Finally, we examined the karyotypes of Ras-transformed tumor cells by performing G-banding analysis. Most of the EM-E6/E7/TERT cells with mutant K-ras had nearly normal karyotypes; only 4% had chromosomal gain or loss, which is similar to the rate for parent EM-E6/E7/TERT cells ( Figure 6 ). These findings indicate that introduction of K-ras did not affect chromosomal integrity, suggesting that the transformed phenotypes are directly due to the function of mutant Kras, rather than due to chromosome changes secondary to K-ras introduction. We also examined the karyotype of EM-E6/E7(TERT) cells transfected with mutant Kras. As expected, these cells had severe chromosomal gain and loss, with chromosome number ranging from 43 to 47, which is similar to the chromosome numbers observed in EM-E6/E7 cells ( Figure 6 ).
Discussion
In the present study, we first established two lines of immortalized cells derived from primary endometrial epithelial cells. The EM-E6/E7/TERT cells had intact chromosomes with stabilized telomeres, and the EM-E6/ E7/(TERT) cells had severe chromosome abnormality owing to progressive shortening of telomeres. However, neither cell line exhibited transformed phenotypes in the subsequent long-term culture. By introducing mutant K-ras alleles into immortalized cells, we created tumorigenic endometrial epithelial cells with intact chromosomes. The present findings suggest that a limited set of genetic factors, including Rb inactivation, telomerase + m u t a n t K -r a s + v e c t o r p a r e n t a l Actin Actin Actin ∼ ∼ ∼ Figure 2 Western blot analysis to assess effects of genetic manipulations in immortalized endometrial epithelial cells. Whole-cell extracts were prepared from EM-E6/E7/TRET cells transfected with various genetic elements, and Western blot analysis was performed with antibodies against PTEN, Akt, phosphorylated Akt (p-Akt), and phosphorylated ERK (p-p42/44). b-Actin was used to equalize for variations in loading.
Creation of tumorigenic endometrial cells Y Mizumoto et al activation and altered K-ras signaling, is sufficient to induce neoplastic transformation, and that widespread genomic changes involving large arrays of cellular genes are not necessary for neoplastic transformation (Figure 7 ). Similar findings have been obtained in studies of human embryonic kidney epithelial cells (Zimonjic et al., 2001) . Recent comparative genomic hybridization analyses have revealed that fewer chromosomes exhibit genomic alterations in endometrial cancer than in other types of tumors (Sonoda et al., 1997) . Such genomic imbalances are rarely observed in endometrial cancers, especially those with defective MMR (Hirasawa et al., 2003) ; this is consistent with the present results. A well-characterized and widely used method of transforming normal human cells is to introduce hTERT, SV40 oncoprotein genes and oncogenic ras (Hahn et al., 1999) . Although that method can efficiently transform normal human cells, widespread genomic alterations frequently occur secondary to introduction of SV40 oncogenes, and those alterations may confound attempts to precisely determine which genetic elements are necessary for neoplastic transformation of normal human cells into tumorigenic derivatives. Thus, the present in vitro system using HPV16 E6/E7 may have advantages for clarification of the molecular pathway of carcinogenesis.
One question that arises from the present findings is why HPV E6 and E7 proteins are apparently necessary 4 cells were seeded on soft agar in 6-cm dishes, and colonies with a diameter of >0.05 mm were counted 14 days after seeding. Bars, 7s.d.; *significantly different from vector control.
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for endometrial carcinogenesis in vitro, despite the fact that HPV infection is not frequently observed in clinical tissue samples of endometrial cancer. We used HPV E6 and E7 as inhibitors of p53 and Rb function. Although genetic abnormality of the Rb locus, including loss of heterozygosity, or altered expression of Rb protein has not frequently been detected in endometrial cancer, alteration of the pathways upstream of Rb, such as aberrant expression of cyclinD1 and cdk4, has been observed in 60-70% of endometrial cancers (Niemann et al., 1997; Semczuk et al., 2004) . Formation of a complex consisting of cyclinD1 and cdk4/6 induces Rb phosphorylation, resulting in activation of E2F, leading to cell cycle progression into the G1 phase. Thus, these pathways appear to be essential for endometrial carcinogenesis in vivo. The present system probably mimics this process by directly inhibiting Rb function (Figure 7) . We are currently testing whether introduction of cyclinD1 and cdk4, instead of HPV E6/E7, into endometrial epithelial cells can reproduce in vitro carcinogenesis.
In the present study, PTEN-knockdown provided no significant transforming ability. Although the inhibition rate of PTEN protein expression was approximately 50% of controls in our system, recent studies suggest that 50% inhibition of PTEN expression by small interfering RNA was sufficient for biologically significant effect of PTEN-knockdown (Tang et al., 2005) . It has been shown by many groups that the major function of PTEN relies on its phosphatase activity by antagonizing the PI3K/AKT pathway (Maehama and Dixon, 1998; Zhao et al., 2003) . However, recent studies demonstrated the crosstalk between PTEN and p53 in vivo. The levels of p53 protein are dramatically reduced in PTEN(À/À) cells and that PTEN stabilizes p53 by increasing its half-life (Stambolic et al., 1998) . Furthermore, PTEN physiologically associates with endogenous p53 and regulates the transcriptional activity of p53 by modulating its DNA-binding activity (Stambolic et al., 1998) . Thus, PTEN mutation acts as oncogenic factor via disabled p53 function. As EM-E6/ E7/TERT cells expressed E6 protein and thereby have impaired p53, the effects of PTEN-knockdown could be minimized in our system. Therefore, to clarify the role of PTEN in endometrial carcinogenesis, it is one way to knowdown PTEN in the absence of E6. In the initial experiment to immortalize primary endometrial epithelial cells, we attempted to introduce HPV16 E7 and hTERT, without introduction of E6. However, we failed to obtain immortalized cells, suggesting that E6 function is necessary for immortalization of endometrial epithelial cells, probably via p53 inactivation. It is thus impossible to realize PTENknockdown in immortalized cells. Alternatively, it is interesting to knockdown PTEN in primary endometrial epithelial cells to find whether it can substitute for E6 for their immortalization.
Introduction of constitutively active Akt conferred on cells the capacity for anchorage-independent. In a recent study, activation of the PI3K pathway in human mammary epithelial cells expressing hTERT and SV40LT conferred the capacity for anchorage-independent growth (Freeman et al., 2003) , consistent with the present findings.
The role of K-ras mutation in endometrial carcinogenesis is greatly clarified by the present results. The present genetic analysis of clinical samples revealed that PTEN and K-ras mutations do not coexist in most endometrial cancers, suggesting that each mutation functions independently as a genetic factor in endometrial carcinogenesis. These results are consistent with the present finding that K-ras mutation alone was sufficient hTERT Figure 7 Proposed molecular pathway of endometrial carcinogenesis. The figure shows multistep barriers to endometrial cellular transformation and the genetic factors required to overcome them. The combination of Rb inactivation (by human papillomavirus (HPV) E6/E7), telomerase activation (by hTERT) and altered k-ras was sufficient for complete transformation of endometrial epithelial cells. Overexpression of cyclinD1 and cdk4, frequently observed in endometrial cancer in vivo, may facilitate Rb inactivation, which may be mimicked by introduction of HPV E6/E7. Akt overexpression confered anchorage-independent growth, but was insufficient for tumorigenicity. In the present model, K-ras mutation alone can transform immortalized endometrial epithelial cells, without PTEN mutation.
for complete transformation of the immortalized endometrial epithelial cells. The present findings also imply that Ras signaling pathways are promising targets for suppression of tumorigenic phenotype of endometrial cancers.
In the present study, we found that the mouse tumors expressing mutant K-ras were poorly differentiated carcinoma without gland-like structures. This is not surprising, because mouse skin models do not facilitate differentiation of cancer cells even though they are derived from well-differentiated carcinomas. Complete differentiation of mouse tumors will require microenvironments, including hormonal actions, which might be achieved by orthotopic implantation. In a recent study, introduction of an androgen receptor allowed characterization of the phenotype of transformed prostate cells in a prostate microenvironment; they had a luminal phenotype reminiscent of organ-confined prostate cancer (Berger et al., 2004) . It would be interesting to test whether implantation of the present tumorigenic endometrial cells into mouse endometrium with administration of exogenous estrogen can produce well-differentiated endometrial cancers.
In summary, we have successfully created tumorigenic human endometrial epithelial cells by introducing specific genetic elements into cells. Introduction of hTERT and inhibition of Rb function at an early stage of passage, along with subsequent introduction of mutant K-ras, generated tumorigenic cells with intact chromosomes. This experimental model provides a foundation for future studies of the specific genetic factors and pathway disruptions required for formation of endometrial cancer. This model also provides a useful platform for testing and development of specific inhibitors of these oncogenic pathways.
Materials and methods
Cell culture
Primary endometrial epithelial cells were obtained from a 42-year-old patient with regular menstrual cycle, who underwent hysterectomy as a treatment of uterine myoma (Kyo et al., 2003) . Immortalized endometrial epithelial cells were basically maintained in Dulbecco's modified Eagle's medium (DMEM)/ F12 (1:1) supplemented with 10% fetal bovine serum (FBS) and ITS (BD Biosciences, Bedford, MA, USA) in an atmosphere of 5% CO 2 at 371C. Tumorigenic endometrial epithelial cells and HeLa cells were maintained in DMEM with 10% FBS.
Tissue sample
Endometrial cancer tissues with endometrioid subtype were obtained from patients who underwent hysterectomy as a treatment of endometrial cancer at the Department of Obstetrics and Gynecology, Kanazawa University. All samples were collected after receiving written, informed consent from the patients. Half of the tissue samples were histologically examined, and the remaining portions of the samples were frozen at À801C until DNA extraction. Tissue samples were used with approval with the Ethics Committee of Kanazawa University.
Telomere length analysis by Southern blotting
Telomere length was analysed with the TRF length assay, using a TeloTTAGGG Telomere Length Assay Kit (Roche Diagnostics, Basel, Switzerland). Briefly, genomic DNA was isolated from cells, and was then analysed by preparing Southern blots and probing them with a telomere-specific probe to visualize the TRF.
Vector construction and retroviral infection
The plasmid pCMSCVpuro contains the CMV/LTR fusion promoter, packaging signal Psi þ , the multicloning sequence from pCLXSN (Imgenex Corp., San Diego, CA, USA), the PGK-puro cassette, and the 3 0 long terminal repeat of murine embryonic stem cell virus (obtained from pMSCVpuro; Clonetech, Mountain View, CA, USA). Construction of pDEST-CMSCVpuro (previously called pCMSCVpuro-DEST) is described elsewhere (Kyo et al., 2003) . Coding sequences of the oncogenic mutant K-ras (Kras-G12V) and an activated form of Akt with a src myristoylation sequence (myrAkt) (Kohn et al., 1996) were first recombined into pDONR201 or pDONR221 (Invitrogen, Carlsbad, CA, USA) by performing the BP reaction according to the manufacturer's instruction, and were then recombined into the destination vector, pDEST-CMSCVpuro, by performing the LR reaction (Invitrogen, Carlsbad, CA, USA) to generate pCMSCVpuro-K-ras* and pCMSCVpuro-myr-Akt. To generate a retrovirus vector expressing PTEN-specific shRNA, the annealed oligos (5 0 gatccccGACATTATGACACCGCC AAttcaagagaTTGGCGGTGTCATAATGTCtttttggaaa3 0 and 5 0 agcttttccaaaaaGACATTATGACACCGCCAAtctcttgaaTT GGCGGTGTCATAATGTCggg3 0 ) were replaced with the stuffer of pENTR221-H1R-stuffer (Sawada et al., 2004) . The shRNA expression cassette was recombined into pDEST-CL-SI-MSCVpuro (previously called pSI-CMSCVpuro-DEST) (Sawada et al., 2004) , by performing the LR reaction (Invitrogen) according to the manufacturer's instruction to generate pCL-SI-MSCVpuro-H1R-PTENRi8. The backbone vector, pCL-SI-MSCVpuro-H1R, was used as a control (Sawada et al., 2004) . Production of recombinant retroviruses is described in detail elsewhere (Kyo et al., 2003) .
Analysis of microsatellite instability
The DNA samples obtained from the endometrial cancers and the myometrium for control were analysed using a panel of five microsatellite markers for the dinucleotide repeat sequences D2S123, D2S147, D10S197, D13S175 and D18S58, as described elsewhere (Katabuchi et al., 1995) . The polymerase chain reaction (PCR) products of the microsatellite markers were analysed using ABI GeneScan (Applied Biosystems, Foster City, CA, USA). The samples were classified as highfrequency MSI (H; PCR bands had shifted, compared with those of the myometrial control samples, for X2 of the five loci), low-frequency MSI (L; 1 locus) or microsatellite-stable (S; no loci) (Boland et al., 1998) .
PTEN and K-ras mutation analysis All nine exons of PTEN and exon 2 of K-ras (including codons 12 and 13) were amplified by PCR using DNAs extracted from endometrial cancer tissues as a template. The primer sets used for PTEN are described elsewhere (Tashiro et al., 1997) . The primers used for K-ras were as follows: forward, 5 0 -GGTA CTGGTGGAGTATTTGATAGTG-3 0 ; reverse, 5 0 -CATG AAAATGGTCAGAGAAACC-3 0 . Polymerase chain reaction products were purified using the Qiagen PCR purification kit (Qiagen, Valencia, CA, USA), and direct sequencing was then performed. Polymerase chain reaction products with suspected mutations were reamplified and subsequently cloned into pGEM-T Easy (Promega, Madison, WI, USA), and at least three of those clones were sequenced.
Western blot analysis
Whole-cell extracts were prepared as previously described. Then, 50-100 mg of the extracts was electrophoresed on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and was then transferred to polyvinylidine difluoride membranes. Membranes were blocked by immersion in TBST (150 mM NaCl, 20 mM Tris-Cl (pH 7.5), 0.1% Tween) containing 5% nonfat dried milk. They were then incubated with specific antibody against Akt, Phospho-Akt Ser473, phospho-p44/42MAPK(Thr202/Tyr204) (Cell Signaling Technology, Danver, MA, USA), PTEN (clone 6H2.1, Cascade Bio Science, Winchester, MA, USA), pan Ras, or b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membranes were next reacted with horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-goat (Jackson Immunoresearch Laboratories, West Grove, PA, USA) immunoglobulin. The LAS3000 CCD-Imaging System (Fujifilm Co. Ltd, Tokyo) was used for detection and quantification of proteins visualized by Lumi-light plus Western blotting substrate (Roche, Basel, Switzerland).
In vitro growth assay Saturation density of EM-E6/E7/TERT cells containing different introduced genetic elements was evaluated by counting cell number on day 8 after seeding 2 Â 10 5 cells in 6-cm dishes and culturing under normal growth conditions in 10% FCS. Growth of EM-E6/E7/TERT cells in low-serum conditions was evaluated by counting cell number on days 2, 3, 4 and 5 after seeding 2 Â 10 5 cells in 6-cm dishes and culturing in 0.5% FCS.
Anchorage independence of growth A total of 1 Â 10 4 EM-E6/E7/TERT cells were seeded in 6-cm dishes containing a top layer of 0.33% noble agar in DMEM supplemented with 10% FCS, and a bottom layer of 0.5% base agar in DMEM supplemented with 10% FCS. Colonies larger than 0.05 mm were counted after incubation for 2 weeks.
Nude mice xenograft experiments EM-E6/E7/TERT cells were resuspended in growth media (10 7 /ml) and subcutaneously injected (0.1 ml) at the base of the left flank of female BALB/c nu/nu mice (age range, 7-9 weeks; SLC, Hamamatsu, Japan). Tumor growth was monitored weekly until certain tumors were visualized or at least for 5 weeks unless tumor formation was detected.
Matrigel invasion assay
Invasiveness of EM-E6/E7/TERT cells was assayed in vitro using a Biocoat Matrigel Invasion Chamber (Becton Dickinson Biosciences, Bedford, MA, USA), as described elsewhere (Sato et al., 1994) . Cells were suspended in the upper wells of Matrigel chambers at 2.5 Â 10 5 cells/chamber, in Eagle's MEM containing 0.1% bovine serum albumin. After 22 h of incubation, cells on the upper surface of the membrane were removed by wiping with cotton swabs, and cells that had migrated through the membrane to the lower surface were fixed with methanol and stained with Mayer's hematoxylin and eosin. The cells on the lower surface of the membrane were counted microscopically as the invasion index. Chemotaxis assays were performed in the same manner as for chemoinvasion, except that the filters were not coated with Matrigel, and the number of cells on the lower surface of the membrane was counted as the migration index. The invasive ability of cells was described as the relative value of invasion index versus migration index.
Statistical analysis
The data from the anchorage-independent growth assay and Matrigel invasion assay were presented as the mean7s.d. of triplicated assays per group. Differences between groups were evaluated using Student's t-test. A P-value of o0.05 was considered to indicate statistical significance.
